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Rectal cancer patients had significantly lower levels of 
methyleneTHF compared with colon cancer patients.
Conclusions There was a large inter-patient variability of 
tissue folate levels in colorectal cancer patients after sup-
plementation with leucovorin at standardised dosage. High 
leucovorin doses were needed to exceed baseline methyl-
eneTHF values, especially in rectal cancer patients. The 
results indicate that the standardised leucovorin dose may 
be insufficient to attain the full antitumour effect of 5-FU. 
Further studies are needed to establish whether higher dos-
age yields a better treatment response.
Keywords Colorectal cancer · Leucovorin · 5-FU-based 
treatment · Methylenetetrahydrofolate · Tetrahydrofolate · 
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Introduction
In 2012, colorectal cancer was the second most diagnosed 
cancer in Europe after breast cancer. Colorectal cancer was 
also responsible for the second highest number of cancer-
related deaths after lung cancer [1]. Currently, the only 
curative therapy for patients with colorectal cancer is sur-
gery with radical removal of the tumour. When the cancer 
is limited to the bowel wall, surgery itself normally attains 
the desired oncologic outcome. In cases of lymph node 
involvement, i.e. stage III disease, there is a high risk of 
tumour recurrence. It has been confirmed in several stud-
ies that a 5-fluorouracil (5-FU)-based chemotherapy regi-
men improves both overall and disease-free survival for 
patients with stage III disease [2–4]. Considering the num-
bers of patients and administered treatments, it is of great 
importance to find methods to tailor or at least optimise 
the therapy. However, even patients with high-risk profiles, 
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Purpose Calcium folinate (leucovorin), which is con-
verted in vivo into biologically active folate, enhances the 
potency of 5-fluorouracil (5-FU)-based chemotherapy in 
colorectal cancer. A common dosage of leucovorin in adju-
vant and palliative settings is 60 mg/m2. The aim was to 
determine the levels of tetrahydrofolate (THF), 5,10-meth-
ylenetetrahydrofolate (methyleneTHF), and 5-methyltet-
rahydrofolate (methylTHF) in tumour and mucosa of colo-
rectal cancer patients who received different dosages of 
leucovorin intravenously at time of surgery.
Methods Eighty patients scheduled for colorectal resec-
tion with indication of colorectal cancer were randomised 
into four groups to receive leucovorin at 0, 60, 200, or 
500 mg/m2, respectively. Blood samples were taken 10 and 
30 min after leucovorin administration. Biopsy samples 
from tumour and mucosa were collected and snap-frozen 
at surgery. The levels of THF, methyleneTHF, and methyl-
THF in tumour and mucosa were assessed by liquid chro-
matography electrospray ionisation tandem mass spectrom-
etry (LC–MS/MS) and the results were related to clinical 
diagnosis and therapeutic regimens.
Results The folate levels in tissue revealed extensive 
inter-individual variability. The mean methyleneTHF value 
for the four treatment groups were 880, 1,769, 3,024 and 
3,723 pmol/gww. Only half of the patients who received 
60 mg/m2 leucovorin had higher levels of methyleneTHF 
in tumour than patients who received 0 mg/m2 leucovorin. 
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such as poorly differentiated tumours without lymph node 
metastasis, could benefit from additional treatment [5] [6]. 
In this post-operative setting, the term adjuvant treatment is 
commonly used. 5-FU-based chemotherapy has also been 
shown to prolong overall survival in palliative settings, i.e. 
for patients with confirmed distant metastasis [7].
5-Fluorouracil was developed in the 1950s by Charles 
Heidelberger, who discovered that rat hepatomas were 
consuming the pyrimidine uracil more rapidly than normal 
rat liver tissue [8]. Thus, uracil was identified as a target 
molecule for chemotherapy. 5-FU is an analogue of uracil 
in which the hydrogen at position 5 is replaced by fluo-
rine. Using the same mechanism to enter the cell as uracil, 
the 5-FU molecule is converted into the active metabolite 
5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP), 
which forms an inhibitory ternary complex with thymi-
dylate synthase (TS) and 5,10-methylenetetrahydrofolate 
(methyleneTHF). This results in the inhibition of thymi-
dylate synthesis and impairment of both DNA synthesis 
and DNA repair. The greatest impact is on cells that are 
rapidly dividing, such as tumour epithelial cells.
The response rate of colorectal tumours to 5-FU mono-
therapy is only around 10 %. By adding the stable calcium 
salt of 5-formyltetrahydrofolic acid (Calciumfolinate), 
which is converted in the liver into methyleneTHF, the 
tumour response rate can be improved to 21 %, as has been 
shown in a meta-analysis [9]. The Nordic FLV therapy, 
which is a combination of 5-FU and leucovorin (REF 12) 
that was introduced in the 1990s, is still the cornerstone of 
both adjuvant and palliative treatments for colorectal can-
cer in Nordic countries. The standard dosage is 500 mg/
m2 5-FU plus 60 mg/m2 leucovorin in the form of calci-
umfolinate, administered as an intravenous infusion 2 days 
in a row. The 2-day treatment is followed by a pause for 
12 days. The standard protocol is usually 6 months long. 
The regimen has been duly updated with the incorporation 
of novel drugs, such as oxaliplatin and antibodies into more 
effective combination therapies. Although it is a well estab-
lished regimen, the evidence for the leucovorin dosage used 
is rather limited. Different regimens used in clinical prac-
tice worldwide apply levels of leucovorin that range from 
20 to 500 mg/m2.
Leucovorin has no intrinsic antitumour effect but it 
enhances the effect of 5-FU by providing the cofactor 
methyleneTHF in abundance and by stabilising the ter-
nary complex [10]. However, leucovorin must first be 
converted in two steps into methyleneTHF, which is the 
active metabolite. This requirement for metabolic activa-
tion may result in inter-individual differences in uptake, 
thereby compromising the benefit gained from the addi-
tion of leucovorin in some of the patients. The leucovorin 
metabolism pathway has been described by Priest and 
colleagues [11].
The impressive advances that have been made in genet-
ics and metabolite measurements (metabolomics) provide 
new possibilities for advanced studies of the folate metabo-
lism and facilitate a better understanding of related cellu-
lar mechanisms. Our research group presented in 2012 an 
LC–MS/MS method that is sufficiently sensitive to sepa-
rate and quantify different forms of folate [12]. Thus, the 
actual concentration of methyleneTHF, and not only of 
total folates, can now be measured in tissue samples. As 
evidenced by our recent findings, using the novel method, 
there is a significant variability in the folate levels in 
tumour and mucosa tissues between patients [13].
The aim of the present study was to determine the lev-
els of different folate forms in tumour and mucosa tissue 
of patients with colorectal cancer who received different 
dosages of leucovorin intravenously at the time of surgery. 
The folate levels were related to the clinical diagnosis and 
therapeutic regimens used.
Patients and methods
The study was approved by the Regional Ethics Commit-
tee in Gothenburg (EPN). Eighty patients scheduled for a 
colorectal resection with a cancer indication were enrolled 
in the study between January 2011 and January 2012. All 
patients gave their written informed consent. The pre-
operative exclusion criteria were patient inability to under-
stand the study information or inability to provide true 
informed consent. There were no other exclusion criteria 
(such as ASA-class, renal function or pre-operative tumour 
stage). The patients were pre-operatively randomised into 
four groups; the first served as control group and received 
no leucovorin. Groups 2, 3, and 4 received 60, 200, and 
500 mg/m2 leucovorin, respectively, administered intrave-
nously at the initiation of general anaesthesia. The leucov-
orin was manufactured in the form of calcium folinate (dl-
leucovorin) supported by Teva Sweden AB Helsingborg. 
The surgeon was blinded to the dosage given. The patients 
were otherwise treated in accordance with normal routines 
and guidelines.
During surgery, at the time of removal of the surgical 
specimen, the research nurse collected fresh tissue sam-
ples from both the tumour and macroscopically normal-
appearing mucosa located 10 cm from the tumour. The 
biopsies were snap-frozen in liquid nitrogen and stored 
at −80 °C until used. The pathology department assessed 
the specimens and provided tumour staging data. Based on 
the routine pathology reports, four patients were excluded 
from the study because the analysis revealed a lack of 
adenocarcinoma tissue; two patients had an obstruction 
related to diverticulitis, one had a squamous epithelial 
cancer, and one had a non-malignant adenoma. During 
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analysis of blood samples, we discovered that one patient 
in treatment group two had received a leucovorin dose that 
was not according to the protocol and this patient is also 
excluded from the study. The main assessment was of the 
folate levels in the mucosa and tumour tissues in relation 
to treatment group. Clinical and pathology data regarding 
diagnosis, tumour differentiation and stage, and pre-opera-
tive treatment regimen were retrieved to assess the different 
groups and enable a better understanding of the factors that 
might influence treatment responses.
Folate analyses
A liquid chromatography electrospray ionisation tan-
dem mass spectrometry (LC–MS/MS) method was used 
to evaluate the levels of the folate derivatives, tetrahy-
drofolate (THF), methyleneTHF, and 5-methyltetrahy-
drofolate (methylTHF) in tumour tissue and adjacent 
mucosa, separately [12].). The LC–MS/MS analyses were 
performed on a waters 2795 LC separation module cou-
pled to a waters micromass Quattro Triple-Quadrupole 
MS system with an electrospray ionisation (ESI) source. 
Folates were detected and quantified using positive elec-
trospray. The separation of folates was performed using an 
Atlantis dC18 3 µm, 2.1*100 mm column (waters) together 
with the guard column Atlantis dC18, 3 µm, 2.1*10 mm. 
The mobile phase consisting of eluent A (0.1 % of acetic 
acid in water) and eluent B (0.1 % acetic acid in acetoni-
trile) was used. The extracted ions following MRM tran-
sitions were monitored at m/z 446 → 299 for THF, m/z 
458 → 311 for methyleneTHF, m/z 460 → 313 for methyl-
THF, and m/z 459 → 312 for Tomudex (IS). On the day of 
sample analysis, extraction buffer was prepared containing 
50 mM phosphate buffer, pH 7.0, 1 % ascorbate, and 0.1 % 
β-mercaptopropanol. The tissue was weighed and placed in 
an Eppendorf vial and a 10× volume of extraction buffer 
was added. Homogenisation was performed using a Tissue-
Lyzer (two disruption steps at 25 Hz for 2.5 min). Tomudex 
was used as an intern standard. After deconjugation, pro-
tein precipitation, centrifugation, and ultrafiltration (30 min 
at 21,500×g at 20 °C) were performed. The solution at 
the bottom of the test tube was used for the LC–MS/MS 
analysis.
Calibration graphs were constructed by plotting the peak 
area ratio of each compound to internal standards against 
concentration. The standards and samples were processed 
using the QuanLynx quantitative processing tool in Mass-
Lynx (Waters Corp., Milford, MA, USA). Intra-batch vari-
ability was determined by analysing tissue Q-samples at 
low, medium, and high concentrations on the same day. 
Inter-assay variability was determined by analysing low, 
medium, and high concentration samples on four separate 
days. The relative standard deviation (RSD) ranged from 
2 to 7 % for all analyses, and the variability over 4 days 
ranged from 3 to 14 % for all analyses. The accuracy of 
the method was determined by estimating the recovery by 
adding known amounts of the standard to a sample. The 
average recoveries were 98, 87, and 93 % for THF, methyl-
eneTHF, and methylTHF, respectively [12].
The levels of THF, methyleneTHF, and methylTHF in 
each sample were expressed as pmol/g wet-weight (pmol/
gww). Due to the known interconversion of methyleneTHF 
and THF, the sum of the concentrations of these two folates 
were also calculated [14].
The plasma samples were frozen, stored, and shipped 
at −80 °C to Charles River Laboratories, UK, where the 
plasma concentrations of methyleneTHF, THF, methylTHF, 
and formyl-THF were analysed using a validated LC–MS/
MS method.
Statistical analyses
The JMP 11.0/SAS software (SAS Institute Inc., Cary, NC, 
USA) was used for the statistical analyses. Nonparametric 
tests; Mann–Whitney/Kruskal–Wallis, and matched-pair 
analyses (Wilcoxon Signed Rank test) were used to exam-
ine differences between the groups. Also presented are 
descriptive statistics with mean or median values and meas-
ures of dispersion, as appropriate. The significance level 
was set at 95 %.
Results
Patients and treatment regimens
Based on clinical diagnosis, 38 patients had colon can-
cer, 37 had rectal cancer, and three patients had cancer 
in both the colon and rectum synchronously. The latter 
three patients were excluded from the statistical analyses 
of folate levels according to tumour location. The demo-
graphic, clinical, and pathologic data are shown in Table 1. 
There were no significant differences regarding age, gen-
der, tumour location, tumour stage, tumour differentiation, 
or lymph status between the four groups. The mean times 
between administration of leucovorin and time of biopsy 
sampling, as well as ranges for the three groups are shown 
in Table 1.
As shown, no statistical differences between the times 
from leucovorin administration to biopsy sampling were 
seen. However, a difference regarding pre-operative treat-
ment was noted; in the control group, there was no patient 
with rectal cancer who had been given pre-operative radia-
tion treatment or neoadjuvant treatment. Regarding safety, 
the administration of the drug was associated with tempo-
rary red cheeks in one patient (given 200 mg/m2 leucovorin) 
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and a short temporary hypotension reaction in one patient 
(given 500 mg/m2). These episodes were considered as 
adverse events. In none of the cases did the adverse reac-
tion lead to any change in the operating procedure.
Folate levels in tumours and mucosa
The mean levels of methyleneTHF, THF, and methyl-
THF were analysed in both tumour and mucosa tissues 
obtained from patients of each treatment group (Table 2). 
The mean level of each folate increased with increasing 
dosage of leucovorin and showed a large inter-patient var-
iation in all treatment groups. The folate levels differed 
significantly between the mucosa and tumour tissues and 
were generally lower in the mucosa of the control group. 
Patients who received 60 or 200 mg/m2 leucovorin had 
significantly higher mean levels of methyleneTHF in their 
tumours, as compared to the levels in their mucosal sam-
ples. After treatment with 500 mg/m2 leucovorin, the dif-
ference in methyleneTHF level between the tumour and 
mucosa samples was no longer statistically significant. 
The same pattern was seen when the THF concentration 
or the sum of methyleneTHF and THF were analysed. No 
significant differences in the levels of methylTHF were 
seen between the tumour and mucosa samples in any of 
the treatment groups. However, in contrast to the other 
folates, the methylTHF level in mucosa of the control 
group was significantly higher compared to the level in 
tumour tissue.
Folate levels and tumour location
There were differences between the folate levels in colonic 
and rectal tumours according to treatment doses. For all 
Table 1  Clinicopathological characteristics of the colorectal cancer patients sub grouped by leucovorin dosage
a
 Neoadjuvant long-term radiation/chemotherapy
Parameter Leucovorin dosage (n)
0 mg/m2 [18] 60 mg/m2 [18] 200 mg/m2 [19] 500 mg/m2 [20]
Age (years)
 Median 73 65.6 70 75.5
 Range 43–89 42–87 37–89 37–87
Sex
 Male 11 12 7 9
 Female 7 6 12 11
Tumour location
 Colon 9 10 8 11
 Rectum 8 8 10 8
 Colon + rectum 1 0 1 1
Primary tumour stage
 1 0 1 1 3
 2 7 9 9 7
 3 9 8 7 8
 4 4 0 2 2
 Data missing 1 0 0 0
Tumour differentiation
 Well 0 0 0 0
 Moderate 14 13 11 12
 Poor 3 2 6 6
 Mucinous 0 3 2 2
 Data missing 1 0 0 0
Pre-operative radiation
 Short-term 0 6 5 2
 Long-terma 0 0 2 1
 Short + long-terma 0 1 7 3
Median time (min) leucovorin 
administration-biopsy sampling 
(mean range):
170 (65–285) 165 (72–457) 163 (65–555)
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treatments groups, the mean methyleneTHF levels in the 
rectal tumours were significantly lower than those in the 
colonic tumours (Table 3; Figs. 1, 2). The difference was 
significant in the groups that received 60 or 200 mg/m2 
leucovorin. The THF level was significantly lower in rectal 
tumours of patients who received 60 mg/m2. As shown in 
Table 3, the methyleneTHF + THF levels were generally 
low in rectal, compared to colon, tumours. In contrast, the 
methylTHF levels were higher in rectal tumour tissues of 
patients who were treated with leucovorin, and a signifi-
cantly higher level was seen after treatment with 60 mg/
m2. As shown in Fig. 2, only 10 (50 %) of the patients 
Table 2  Comparison of mean ± SD folate levels in tumour and mucosa tissues of the colorectal cancer patients
Folate levels in pmol/gww
μg/L plasma
P value by Wilcoxon Signed Rank test
a
 Concentration in plasma
Folate form Tissue type Leucovorin dosage (n)
0 mg/m2 [18] 60 mg/m2 [18] 200 mg/m2 [19] 500 mg/m2 [20]
THF Tumour 136 ± 88 249 ± 97 490 ± 353 543 ± 279
Mucosa 103 ± 59 210 ± 96 289 ± 153 455 ± 282
P value 0.030 0.091 <0.0001 0.12
MethyleneTHF Tumour 880 ± 412 1,769 ± 818 3,024 ± 1,941 3,773 ± 1,425
Mucosa 669 ± 221 1,377 ± 470 1,883 ± 471 3,062 ± 1,445
P value 0.0016 0.022 0.0003 0.090
MethyleneTHF + THF Tumour 1,016 ± 475 2,018 ± 888 3,514 ± 2,109 4,266 ± 1,563
Mucosa 772 ± 265 1,587 ± 536 2,173 ± 461 3,517 ± 1,607
P value 0.010 0.018 0.0002 0.070
MethylTHF Tumour 141 ± 86 1,056 ± 348 2,544 ± 959 4,129 ± 1,293
Mucosa 189 ± 111 1,066 ± 384 2,295 ± 501 4,095 ± 2,093
P value 0.0047 0.93 0.46 0.49
Leucovorin (mean/range)a
 10 min Non applicable 11,377 ± 2,225 30,900 ± 6,176 93,625 ± 1,872
 30 min 8,199 ± 1,238 27,684 ± 41,013 69,445 ± 9,172
Table 3  Comparison of mean ± SD folate levels in tumour tissues of the colorectal cancer patients by tumour location
Folate levels in pmol/gww
P value by Kruskal–Wallis test (2-sample Test)
Folate form Tumour location Leucovorin dosage (n)
0 mg/m2 [17] 60 mg/m2 [18] 200 mg/m2 [18] 500 mg/m2 [19]
THF Colon 143 ± 62 306 ± 79 508 ± 240 522 ± 164
Rectum 139 ± 121 178 ± 67 497 ± 446 494 ± 317
P value 0.41 0.0067 0.18 0.24
MethyleneTHF Colon 1,016 ± 482 2,214 ± 779 4,207 ± 2,590 4,222 ± 1,285
Rectum 747 ± 230 1,213 ± 454 2,162 ± 406 3,222 ± 1,530
P value 0.26 0.024 0.0029 0.066
MethyleneTHF + THF Colon 1,159 ± 537 2,520 ± 826 4,715 ± 2,821 4,744 ± 1,397
Rectum 886 ± 328 1,391 ± 477 2,659 ± 696 3,716 ± 1,726
P value 0.26 0.0088 0.019 0.094
MethylTHF Colon 162 ± 99 1,257 ± 201 2,331 ± 757 4,022 ± 1,551
Rectum 123 ± 63 806 ± 338 2,795 ± 1,100 4,163 ± 1,119
P value 0.46 0.0067 0.56 0.54
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given 60 mg/m2 leucovorin achieved a methyleneTHF 
level in their tumour tissues that was above the highest 
value of any patient in the control group (1,714 pmol/gww). 
At 200 mg/m2 leucovorin, all patients, except one, reached 
methyleneTHF levels >1,714 pmol/gww, and at 500 mg/m2 
leucovorin, all patients had methyleneTHF levels above 
the level of the controls. Data were weighted according to 
time to vessel ligation, which was a parameter suspected 
to affect the tissue folate levels. However, this did not 
affect the significant differences between colon and rectal 
tumour tissue.
Blood analysis
A strong correlation was noted between the levels of leu-
covorin in blood samples collected 10 and 30 min after the 
given dose of calcium folinate and the levels of the differ-
ent folate forms in both tumour and mucosa samples. How-
ever, there was no correlation between the blood levels of 
leucovorin and levels of folate in tissue in relation to the 
administered dosage of the drug.
Discussion
The role of leucovorin in 5-FU-based chemotherapy is to 
increase the level of the cofactor methyleneTHF needed to 
stabilise the ternary complex consisting of FdUMP, methyl-
eneTHF, and TS in tumour cells. Thereby, the production of 
thymidine is inhibited leading to an impaired DNA synthe-
sis and DNA repair. The continuous development of assess-
ment techniques and new biochemical methods provide 
tools to study different metabolites in more sophisticated 
ways. In the present study, a sensitive LC–MS/MS method 
was used to analyse metabolically active folate metabolites, 
including methyleneTHF.
A notable finding of the study was that only 50 % of the 
patients who received the common dose of 60 mg/m2 leu-
covorin achieved methyleneTHF levels in the tumour tissue 
that were higher than those detected in patients of the con-
trol group. In contrast, in the group that received 200 mg/
m2 leucovorin, only one patient did not reach the highest 
methyleneTHF level of the controls. Furthermore, in the 
group that received 500 mg/m2 leucovorin, all patients had 
a methyleneTHF level well above the controls. This indi-
cates that in a large number of patients low levels of folates 
accumulated in the tumour, possible because of limited 
folate polyglutamylation. Another important finding was 
the significant difference in methyleneTHF and THF levels 
between the colorectal tumour tissue and the macroscopi-
cally normal-appearing mucosa (Table 2). This difference 
was observed in patients who had not received any treat-
ment and was even more pronounced in those patients who 
received leucovorin at a dosage of 60 or 200 mg/m2.
The study raises the question whether the commonly 
used dosage of leucovorin might result in a sub-optimal 
concentration of methyleneTHF in the tumour tissue to pro-
vide an optimal effect of 5-FU treatment. If this is the case, 
several patients with colorectal cancer might be receiving 
inadequate treatment and may benefit from leucovorin con-
centrations as high as 200–500 mg/m2. Similar conclusions 
were drawn by Schlemmer et al. [15] in a study published 
in 2008, which showed significant higher values regarding 
reduced folates in tumour tissues as well as in liver metas-





































Fig. 1  Comparison of the methyleneTHF concentration in tumour 
tissue of patients with colon (n = 29) or rectal (n = 28) cancer after 
FLV treatment. Each circle represents an individual patient. As 
shown, patients with rectal cancer had lower levels of methyleneTHF 
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Fig. 2  Comparison of the methyleneTHF levels in tumour tissue of 
patients with colon or rectal cancer after supplementation with 0, 60, 
200, or 500 mg/m2 leucovorin in combination with 5-FU. Individual 
patients with colon cancer are represented by blue dots, rectal cancer 
patients with red dots. The horizontal line marks the highest meth-
yleneTHF concentration found in the control patients (1,714 pmol/
gww). As shown, the tumoural methyleneTHF levels in rectal cancer 
patients were generally lower than in colon cancer patients after treat-
ment with leucovorin
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Adding to the complexity, there was a high inter-indi-
vidual variation in the methyleneTHF levels in the tumours 
(Fig. 2). Polymorphisms in genes that code for folate-asso-
ciated enzymes, such as methylenetetrahydrofolate reduc-
tase, could be a part of the explanation for this phenom-
enon [16–19]. Different activity of the enzymes needed in 
conversion of leucovorin to methyleneTHF could also play 
a role, as indeed could different starting levels of the tis-
sue folates. Therefore, it is difficult to predict the levels of 
tissue folates that will be reached in an individual patient, 
in response to a given leucovorin dose based solely on the 
body surface area. However, since leucovorin is not con-
sidered to be a toxic substance and only a few and mild 
adverse events were reported in the present study, fur-
ther studies with high leucovorin supplementation levels 
(200–500 mg/m2) could be reasonably pursued. Hypotheti-
cally, high doses of leucovorin would make an abundance 
of methyleneTHF available for ternary complex formation 
between methyleneTHF, FdUMP, and TS, despite pos-
sible rate-limiting steps or local folate deficiencies. The 
results further showed clear differences in the folate lev-
els in relation to tumour location. The methyleneTHF and 
THF + methyleneTHF levels differed significantly between 
patients with colon and rectal cancer (Table 3). For all 
treatment groups, the levels were lower for rectal cancers. 
No significant difference was seen between patients treated 
or not treated with neoadjuvant therapy.
Post-operative adjuvant chemotherapy was previously 
less established for cases of rectal cancer than for cases 
of colon cancer, but is now recommended in the Swedish 
national guidelines in selected cases. Based on the results 
of our study, it appears that the administered concentra-
tion of leucovorin in the standard treatment is inadequate 
for patients with rectal cancer in that it yields a clinically 
insufficient concentration of methyleneTHF in the tumour 
tissue. This finding may explain why the evidence for a 
beneficial application of adjuvant treatment with 5-FU-
based chemotherapy has not been as clear in rectal cancer 
as they are in colon cancer [20, 21].
The present study draws attention to several issues. 
The findings raise the question as to whether previous 
assumptions made regarding leucovorin dosages are cor-
rect. It also shows that new techniques and advances in 
associated scientific areas make revaluation of previ-
ously studied subjects both worthwhile and important. As 
the present study was limited in terms of the numbers of 
patients, the results needs to be confirmed in a larger study. 
Among the strengths of the study are the broad inclusion 
criteria, reflecting clinical reality, and the randomisation 
of the patients to the treatment groups. The randomisation 
should negate selection bias, although skewing was noted 
between patient groups in terms of neoadjuvant treatment; 
no patient in the control group received any pre-operative 
radiotherapy. Because a high turnover of folates might 
be required during repair of radiation-damaged tissue, 
the mean folate level at base line could be anticipated to 
be lower if the rectal cancer patients of the control group 
had been subjected to radiotherapy. However, we could not 
detect any differences in the folate levels between patients 
treated or not treated with radiotherapy. Furthermore, both 
higher (methylTHF) and lower (methyleneTHF) folate 
levels were found in rectal tumours as compared to colon 
tumours, after leucovorin supplementation. Thus, there 
seems to be inherent differences in the response to leucov-
orin treatment between rectal and colon cancer.
The possibility exists that the difference in folate lev-
els noted is a systematic bias due to treatment or surgical 
issues, including differences in the time passed after ves-
sel ligation until biopsy sampling. However, this potential 
confounder was tested for by including the time to vessel 
ligation in the statistical analysis and did not significantly 
affect the results. In a recent study, Sadahiro et al. showed 
that leucovorin administration significantly increased the 
reduced folate levels in colorectal cancer tissue and adja-
cent mucosa. The increase lasted until 18 h for mucosa and 
12 h for colorectal cancer tissue [22]. However, in a clinical 
setting, the time span from the leucovorin administration 
until infusion of chemotherapy is usually no longer than 
30–90 min. It can also be debated as to whether the fact 
that a tumour is a very heterogenic tissue has an important 
influence on the measured folate concentrations depending 
on how the biopsies are collected. In the present study, we 
have tried to address this problem by having the same two 
research nurses collecting tissues in a standardised way. 
The data suggest that our results are comparable to previ-
ous results reported in the literature [14, 23, 24].
A last and major challenge is the difficulty of extrapolat-
ing the findings into adjuvant treatment settings, as any vis-
ible tumour tissue has been removed by the time adjuvant 
treatment starts. Thus, the treatment effect will be exerted 
on normal tissues and, hopefully, on remaining circulating 
tumour cells or cell aggregations. The nature of this issue 
itself presents challenges that need to be resolved in order 
to achieve treatment improvements.
Conclusions
The results of this study showed a large inter-patient vari-
ability of folate levels in tumour and mucosa tissue of colo-
rectal patients after supplementation with leucovorin at the 
standardised dosage. The low levels of methyleneTHF were 
most prominent in rectal cancer patients, where high leuco-
vorin doses were needed to exceed baseline methyleneTHF 
values in tumour. The results of this study indicate that the 
standardised dose may be sub-optimal since the achieved 
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concentration of methyleneTHF in tissues of the patients 
may be insufficient to get an optimal antitumour effect of 
5-FU. On going studies will establish if a higher concentra-
tion of leucovorin yields a better treatment response.
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